FDA Still Not Comfortable With New Vaccine Adjuvants, Industry Veterans Say
Executive Summary
The wave of new adjuvant-boosted vaccines under development promises to protect new and broader populations against a host of previously elusive pathogens - including pandemic flu. However, until FDA has more experience with these novel combinations, the regulatory hurdles will remain high, speakers warned at the recent Immunotherapeutics & Vaccine Summit in Cambridge, Mass
You may also be interested in...
Therapeutic Cancer Vaccines Can Use Adjuvants, FDA Says
But even though the agency’s final guidance on cancer vaccines adds a section on adjuvants, the additional data requirements that FDA will request remain relatively vague.
Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA
Industry is calling on FDA to write separate rules for assessing adjuvants. This would encourage innovation in immunotherapies, the Biotechnology Industry Organization and Pharmaceutical Research and Manufacturers of America contend.
Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA
Industry is calling on FDA to write separate rules for assessing adjuvants. This would encourage innovation in immunotherapies, the Biotechnology Industry Organization and Pharmaceutical Research and Manufacturers of America contend.